rct
    2011
    High Quality

    The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study

    Barton DL, Atherton PJ, Bauer BA

    Published in The Journal of Supportive Oncology

    Methodology

    Phase III randomized placebo-controlled double-blind trial of valerian 450 mg at bedtime for 8 weeks in patients undergoing cancer treatment

    Key Findings

    The primary Pittsburgh Sleep Quality Index outcome did not differ significantly from placebo, though fatigue measures improved

    Conclusions

    Valerian did not improve overall sleep quality in cancer patients despite some benefit for fatigue

    Limitations

    Primary endpoint null; heterogeneous cancer population

    Supplements Studied

    The primary Pittsburgh Sleep Quality Index outcome did not differ significantly from placebo

    Related Health Concerns

    Poor Sleep Quality
    Cancer

    Study Details

    Year:2011
    Sample Size:227
    Duration:8 weeks
    Quality Score:7/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.